切换至 "中华医学电子期刊资源库"

中华腔镜外科杂志(电子版) ›› 2021, Vol. 14 ›› Issue (05): 271 -276. doi: 10.3877/cma.j.issn.1674-6899.2021.05.004

论著 上一篇    下一篇

腹腔镜微波消融治疗≤3 cm肝细胞肝癌的临床疗效分析
陈亚峰 1, 李江斌 1, 钟文钧 1, 董瑞 1 , ( ), 臧莉 1, 阴继凯 1, 杜锡林 1, 鲁建国 1   
  1. 1. 710038 西安,空军军医大学第二附属医院普通外科
  • 收稿日期:2021-08-20 出版日期:2021-10-30
  • 通信作者: 董瑞
  • 基金资助:
    陕西省重点研发计划项目(2020SF-067)

Clinical effect analysis of laparoscopic microwave ablation for HCC ≤ 3 cm

Yafeng Chen 1, Jiangbin Li 1, Wenjun Zhong 1, Rui Dong 1 , ( ), Li Zang 1, Jikai Yin 1, Xilin Du 1, Jianguo Lu 1   

  1. 1. Department of General Surgery, The Second Affiliated Hospital, Air Force Military Medical University, Xi’an 710038, China
  • Received:2021-08-20 Published:2021-10-30
  • Corresponding author: Rui Dong
目的

探讨经腹腔镜微波消融术(laparoscopic microwave ablation,LMWA)治疗≤3 cm肝细胞肝癌(hepatocellular carcinoma,HCC)的临床疗效。

方法

回顾性分析2015年1月至2016年8月空军军医大学第二附属医院普通外科收治的166例HCC患者的临床资料。依据手术方式分为LMWA组90例、腹腔镜肝切除术(laparoscopic hepatectomy,LH)组76例。比较两组的临床疗效和安全性。

结果

LMWA组的手术时间、术中出血量、胃肠功能恢复时间、腹腔引流管拔除时间、术后住院时间明显少于LH组,差异有统计学意义(P<0.05)。LMWA组术后2 d的WBC、ALT、TBIL、PT显著低于LH组,ALB显著高于LH组,差异有统计学意义(P<0.05)。两组的发热、腹腔出血、胆漏、肝周脓肿、胸腔积液、腹水比较,差异无统计学意义(P>0.05)。术后1个月,LMWA组的客观缓解率为96.67%,稍低于LH组的100.00%,但差异无统计学意义(P>0.05)。LMWA组术后1、3、5年总体生存率分别为96.67%、85.56%、73.33%,LH组分别为97.37%、86.84%、75.00%,差异无统计学意义(P>0.05)。LMWA组术后1、3、5年无病生存率分别为93.33%、77.78%、54.44%,LH组分别为94.74%、80.26%、56.58%,差异无统计学意义(P>0.05)。

结论

LMWA治疗≤3 cm且无血管侵犯的单发肝细胞肝癌是安全、可行、有效的。与LH相比,近期效果和远期效果可观。

Objective

To investigate the clinical efficacy of laparoscopic microwave ablation on hepatocellular carcinoma(HCC)≤3 cm.

Methods

Clinical data of 166 HCC patients in Department of General Surgery, The Second Affiliated Hospital, Air Force Military Medical University from Jan. 2015 to Aug. 2016 were retrospectively analyzed. According to surgical procedure, the patients were divided into laparoscopic microwave ablation group(LMWA group)and laparoscopic hepatectomy group(LH group). The clinical efficacy and safety of the two groups were compared.

Results

The operation time, intraoperative blood loss, gastrointestinal function recovery time, abdominal drainage tube removal time and postoperative hospital stay in the LMWA group were significantly shorter than those in the LH group, with statistically significant differences between groups(P<0.05). WBC, ALT, TBIL and PT in LMWA group were significantly lower than those in LH group(P<0.05), and ALB in LMWA group was significantly higher than that in LH group(P<0.05), and the difference was statistically significant. There were no significant differences in fever, abdominal bleeding, biliary leakage, perihepatic abscess, pleural effusion and abdominal effusion between the two groups(P>0.05). The overall response rate of LMWA group 1 month postoperative was 96.67%, slightly lower than that of LH group (100.00%), but the difference was not statistically significant(P>0.05). The overall survival rates at 1, 3 and 5 years after operation were 96.67%, 85.56% and 73.33% in the LMWA group and 97.37%, 86.84% and 75.00% in the LH group, respectively, with no statistical significance(P>0.05). The disease-free survival rates at 1, 3 and 5 years after operation were 93.33%, 77.78% and 54.44% in LMWA group and 94.74%, 80.26% and 56.58% in LH group, respectively, and the difference was not statistically significant(P>0.05).

Conclusions

Laparoscopic microwave ablation is safe, feasible and effective in the treatment of single hepatocellular carcinoma ≤3 cm without vascular invasion. Compared with laparoscopic hepatectomy, the short-term and long-term effects are considerable.

表1 两组肝细胞肝癌患者一般资料比较
表2 两组肝细胞肝癌患者手术情况比较( ±s)
表3 两组肝细胞肝癌患者术后2 d化验指标比较( ±s)
表4 术后两组肝细胞肝癌患者并发症比较[例(%)]
表5 术后1个月两组肝细胞肝癌患者治疗效果比较[例(%)]
表6 两组肝细胞肝癌患者术后总体生存和无瘤生存比较[例(%)]
1
Bureau of Medical Administration, National Health Commission of the People′s Republic of China. Standardization for diagnosis and treatment of hepatocellular carcinoma (2019 edition)[J]. Chin J Dig Surg202019(1): 1-20.
2
Yoshida H, Taniai N, Yoshioka M, et al. Current status of laparoscopic hepatectomy[J]. J Nippon Med Sch201986(4): 201-206.
3
Solaini L, Bocchino A, Cucchetti A, et al. Anatomic laparoscopic liver resection in the scenario of the hepatocellular carcinoma: a systematic review and meta-analysis[J]. Journal of Laparoendoscopic & Advanced Surgical Techniques202030(10): 1076-1081.
4
Wu D, Yang Y, Chen J, et al. Three different ways of treating primary hepatocellular carcinoma at an early stage: a prospective comparative study[J]. Gastroenterol Res Pract20202020(12): 1-6.
5
Izzo F, Granata V, Grassi R, et al. Radiofrequency ablation and microwave ablation in liver tumors: an update[J]. Oncologist201924(10): 990-1005.
6
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin2018, 68(6): 394-424.
7
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology201867(1): 358-380.
8
Cheung TT, Dai WC, Tsang SH, et al. Pure laparoscopic hepatectomy versus open hepatectomy for hepatocellular carcinoma in 110 patients with liver cirrhosis: a propensity analysis at a single center[J]. Ann Surg2016264(4): 612-620.
9
Ratti F, Barkhatov LI, Tomassini F, et al. Learning curve of selftaught laparoscopic liver surgeons in left lateral sectionectomy: results from an international multi-institutional analysis on 245 cases[J]. Surg Endosc201630(8): 3618-3629.
10
Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis[J]. World J Surg Oncol201917(1): 98.
11
Jin T, Liu X, Dai C, et al. Beneficial impact of microwave ablation-assisted laparoscopic hepatectomy in cirrhotic hepatocellular carcinoma patients: a propensity score matching analysis[J]. Int J Hyperthermia201936(1): 530-537.
12
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol201869(1): 182-236.
13
Ricci AD, Rizzo A, Bonucci C, et al. The (eternal) debate on microwave ablation versus radiofrequency ablation in BCLC-A hepatocellular carcinoma[J]. In Vivo202034(6): 3421-3429.
14
Gupta P, Maralakunte M, Kumar- MP, et al. Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis[J]. Eur Radiol202131(7): 5400-5408.
15
Poulou LS, Botsa E, Thanou I, et al. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma[J]. World J Hepatol20157(8): 1054-1063.
16
Mori Y, Tamai H, Shingaki N, et al. Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma[J]. Hepatol Int20093(3): 509- 515.
17
Piskin FC, Balli HT, Aikimbaev K. Safety and efficacy analysis of microwave ablation in small hepatocellular carcinomas sized below 3 cm[J]. Pol J Radiol202085(1): 202-208.
18
Santambrogio R, Chiang J, Barabino M, et al. Comparison of laparoscopic microwave to radiofrequency ablation of small hepatocellular carcinoma (≤3 cm)[J]. Ann Surg Oncol201724(1): 257-263.
19
Leuchte K, Staib E, Thelen M, et al. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma[J]. Cancer Immunol Immunother202170(4): 893-907.
20
Della Corte A, Ratti F, Monfardini L, et al. Comparison between percutaneous and laparoscopic microwave ablation of hepatocellular carcinoma[J]. Int J Hyperthermia202037(1): 542-548.
21
Eun HS, Lee BS, Kwon IS, et al. Advantages of laparoscopic radiofrequency ablation over percutaneous radiofrequency ablation in hepatocellular carcinoma[J]. Dig Dis Sci201762(9): 2586-2600.
22
陈焕伟,罗发,刘颖,等.腹腔镜解剖性肝切除治疗位于中央部位肝癌单中心经验[J/CD]. 中华腔镜外科杂志(电子版)202114(1): 19-23.
23
Zhang M, Ma H, Zhang J, et al. Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis[J]. Onco Targets Ther201710(3): 4829-4839.
[1] 王隽, 宁飞龙, 张颢, 刘阳, 权红光, 严金明. 多层螺旋CT扫描与图像后处理在腹股沟疝术前分型的评估效能[J]. 中华疝和腹壁外科杂志(电子版), 2021, 15(05): 466-470.
[2] 孟培, 戴平, 邵志鸿. 腹腔镜腹壁疝修补术对切口疝患者的临床疗效及胃肠功能的影响[J]. 中华疝和腹壁外科杂志(电子版), 2021, 15(05): 485-488.
[3] 何恒正, 程发辉, 梁红燕, 张宇, 曾辉, 谭礼鹏, 周艳. 生物补片在食管裂孔疝修补术中应用的疗效[J]. 中华疝和腹壁外科杂志(电子版), 2021, 15(05): 489-492.
[4] 孙畅, 臧春宝. 腹腔镜完全腹膜外疝修补术治疗老年腹股沟疝的疗效及对血清胃泌素和胃动素的影响[J]. 中华疝和腹壁外科杂志(电子版), 2021, 15(05): 493-496.
[5] 江涛. 腹腔镜下经腹腹膜前疝修补术后慢性疼痛的风险模型构建[J]. 中华疝和腹壁外科杂志(电子版), 2021, 15(05): 512-516.
[6] 曹瑶, 朱青, 李建华. 腹腔镜下小儿腹股沟疝的围手术期护理[J]. 中华疝和腹壁外科杂志(电子版), 2021, 15(05): 525-527.
[7] 王祉, 王卡娜, 闵玲, 杨帆, 綦小蓉, 郑莹. 妊娠期行经脐单孔腹腔镜附件手术14例临床分析[J]. 中华腔镜外科杂志(电子版), 2021, 14(05): 304-308.
[8] 马欢, 马德林, 靳斌. 完全腹腔镜下Ⅲa型肝门部胆管癌根治术[J]. 中华腔镜外科杂志(电子版), 2021, 14(05): 309-311.
[9] 丁国平, 俞一尘, 曹利平. 腹腔镜胰颈部肿瘤切除联合胰管支架置入术[J]. 中华腔镜外科杂志(电子版), 2021, 14(05): 312-314.
[10] 狐鸣, 马世勋, 杨婧, 田宏伟, 詹渭鹏, 苗长丰, 房伟, 陈东东, 景武堂, 郭进, 邓渊, 黄显斌, 马云涛, 蔡辉. 吸引器在达芬奇机器人"3+2"辅助胃癌根治术中的应用体会[J]. 中华腔镜外科杂志(电子版), 2021, 14(05): 260-264.
[11] 术者:张树彬 助手:邢中强 段佳悦 李昂 指导老师:刘建华 剪辑:徐晨. 健侧先行原位右半肝+全尾状叶切除的腹腔镜肝门部胆管癌根治术[J]. 中华肝脏外科手术学电子杂志, 2021, 10(06): 0-.
[12] 褚薛慧. 腹腔镜肝右后叶切除术[J]. 中华肝脏外科手术学电子杂志, 2021, 10(06): 0-.
[13] 卢攀 刘心怡 李坚 陈龙 张伟. 经脐单孔腹腔镜左半肝切除术[J]. 中华肝脏外科手术学电子杂志, 2021, 10(06): 0-.
[14] 王庆亮, 李晓杰, 胡昆鹏, 许世磊, 林继宗, 刘波. CD31内皮细胞抗体靶向荧光成像在肝段标记中的实验研究[J]. 中华肝脏外科手术学电子杂志, 2021, 10(05): 524-529.
[15] 蓝炘, 朴成林, 安峰铎, 谈明坤, 司振铎, 吴蔚, 赵娜, 冷建军. 3D腹腔镜与2D腹腔镜下肝癌切除术的短期疗效比较[J]. 中华临床医师杂志(电子版), 2021, 15(05): 327-330.
阅读次数
全文


摘要